[
  {
    "ts": "2026-02-02T13:00:00+00:00",
    "headline": "Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months",
    "summary": "Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in r",
    "url": "https://finance.yahoo.com/news/real-world-head-head-analysis-130000943.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "e920c1bc-d19b-3b4f-b932-72c10c3f9f9b",
      "content": {
        "id": "e920c1bc-d19b-3b4f-b932-72c10c3f9f9b",
        "contentType": "STORY",
        "title": "Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months",
        "description": "",
        "summary": "Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in r",
        "pubDate": "2026-02-02T13:00:00Z",
        "displayTime": "2026-02-02T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721",
          "originalWidth": 400,
          "originalHeight": 38,
          "caption": "Johnson & Johnson (PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GXCxbsFDDz3fFTI03HwuBw--~B/aD0zODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 400,
              "height": 38,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qhQKh0p3toIAfsx9SijYTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/real-world-head-head-analysis-130000943.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/real-world-head-head-analysis-130000943.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T14:51:53+00:00",
    "headline": "Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Hottest Stocks to Buy in 2026. On January 28, TheFly reported that Morgan Stanley upgraded Johnson & Johnson (NYSE:JNJ) from Equal Weight to Overweight, increasing the price target from $200 to $262. Terence Flynn from Morgan Stanley remains bullish on the company as he expects higher […]",
    "url": "https://finance.yahoo.com/news/morgan-stanley-upgrades-johnson-johnson-145153987.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "324c2382-0838-398c-97b0-5298c2375c4d",
      "content": {
        "id": "324c2382-0838-398c-97b0-5298c2375c4d",
        "contentType": "STORY",
        "title": "Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Hottest Stocks to Buy in 2026. On January 28, TheFly reported that Morgan Stanley upgraded Johnson & Johnson (NYSE:JNJ) from Equal Weight to Overweight, increasing the price target from $200 to $262. Terence Flynn from Morgan Stanley remains bullish on the company as he expects higher […]",
        "pubDate": "2026-02-02T14:51:53Z",
        "displayTime": "2026-02-02T14:51:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V.cYaSHzzKzVHdGmA_7kFQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WQYQ_aVrFtQIDc0.PoEAUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-upgrades-johnson-johnson-145153987.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-upgrades-johnson-johnson-145153987.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]